424 related articles for article (PubMed ID: 35496824)
1. All
Bahlool AZ; Grant C; Cryan SA; Keane J; O'Sullivan MP
Curr Res Immunol; 2022; 3():54-72. PubMed ID: 35496824
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
[TBL] [Abstract][Full Text] [Related]
4. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
[TBL] [Abstract][Full Text] [Related]
5. Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis.
Bahlool AZ; Fattah S; O'Sullivan A; Cavanagh B; MacLoughlin R; Keane J; O'Sullivan MP; Cryan SA
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015371
[TBL] [Abstract][Full Text] [Related]
6. Host-Directed Therapeutic Strategies for Tuberculosis.
Kolloli A; Subbian S
Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
[TBL] [Abstract][Full Text] [Related]
7. All-trans Retinoic Acid Augments Autophagy during Intracellular Bacterial Infection.
Coleman MM; Basdeo SA; Coleman AM; Cheallaigh CN; Peral de Castro C; McLaughlin AM; Dunne PJ; Harris J; Keane J
Am J Respir Cell Mol Biol; 2018 Nov; 59(5):548-556. PubMed ID: 29852080
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the mTOR Pathway for Tuberculosis Treatment.
Singh P; Subbian S
Front Microbiol; 2018; 9():70. PubMed ID: 29441052
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
10. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
11. Microfluidics produced ATRA-loaded PLGA NPs reduced tuberculosis burden in alveolar epithelial cells and enabled high delivered dose under simulated human breathing pattern in 3D printed head models.
Bahlool AZ; Cavanagh B; Sullivan AO; MacLoughlin R; Keane J; Sullivan MPO; Cryan SA
Eur J Pharm Sci; 2024 May; 196():106734. PubMed ID: 38417586
[TBL] [Abstract][Full Text] [Related]
12. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
13. Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation.
Ahmed S; Raqib R; Guðmundsson GH; Bergman P; Agerberth B; Rekha RS
Antibiotics (Basel); 2020 Jan; 9(1):. PubMed ID: 31936156
[TBL] [Abstract][Full Text] [Related]
14. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
15. Host-Directed Therapies for Tuberculosis.
Jeong EK; Lee HJ; Jung YJ
Pathogens; 2022 Nov; 11(11):. PubMed ID: 36365041
[TBL] [Abstract][Full Text] [Related]
16. Autophagy: A new strategy for host-directed therapy of tuberculosis.
Paik S; Kim JK; Chung C; Jo EK
Virulence; 2019 Dec; 10(1):448-459. PubMed ID: 30322337
[TBL] [Abstract][Full Text] [Related]
17. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
18. Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy.
Ouyang Q; Zhang K; Lin D; Feng CG; Cai Y; Chen X
mSphere; 2020 Apr; 5(2):. PubMed ID: 32269154
[TBL] [Abstract][Full Text] [Related]
19. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
Palucci I; Delogu G
Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
